Q-omics provides the consensus-scored LRRC37B profile across patient tissues and cancer cell-line models. LRRC37B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRRC37B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LRRC37B RNA expression shows 21,335 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where LRRC37B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37B survival associations across molecular data types. LRRC37B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37B RNA expression–survival associations across cancer types. High LRRC37B expression shows unfavorable associations in MESO, KICH and ACC, but favorable associations in SKCM, LUAD and PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LRRC37B RNA expression.
This table summarizes LRRC37B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37B shows higher tumor expression in KIRC, KIRP, BLCA, LIHC, HNSC and CHOL. The KIRC box plot shows higher LRRC37B RNA expression in tumor versus normal tissue (log2 FC = +0.724, t-test p < 0.001).
This table shows molecular features associated with LRRC37B in patient tissues and cancer cell lines. In patient samples, LRRC37B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
